Drug General Information (ID: DDICMOA053)
Drug Name			Ceritinib		Drug Info		Levobetaxolol (ophthalmic)		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Multikinase Inhibitors				Cardiotonic Agents
Structure

Mechanism of Ceritinib-Levobetaxolol (ophthalmic) Interaction (Severity Level: Major)
Increased risk of bradycardia Click to Show/Hide Mechanism Graph
Drug Name		Ceritinib				Levobetaxolol (ophthalmic)
Mechanism		Bradycardia				Bradycardia
Key Mechanism Factor 1
		Factor Name		Bradycardia
		Factor Description		Bradycardia is a slow heart rate in which the heart beats less than 60 times per minute. If the heart rate is very slow and the heart is not pumping enough oxygen-rich blood to the body, and you may feel dizzy, very tired or weak, and short of breath.
Mechanism Description		Increased risk of bradycardia by the combination of Ceritinib and Levobetaxolol (ophthalmic)

Recommended Action
Management		Concomitant use of ceritinib with other agents known to cause bradycardia should be avoided if possible. All patients treated with ceritinib should have their heart rate and blood pressure monitored regularly. Consult the product labeling for dosage adjustment and management recommendations if symptomatic or life-threatening bradycardia occurs. Patients should be advised to notify their doctor if they experience irregular heartbeat, slow pulse, dizziness, or syncope.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.